European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT – Technetium, PET – F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Thyroid, Cardiology) – Forecasts to 2020

“The European nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country. The European nuclear medicine/radiopharmaceuticals market is valued at USD 1.095 billion in 2015 and is poised to grow at a CAGR of 8.2% during the forecasted period.

Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, cyclotron based production are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.

Some of the major players in the European nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the European market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the European nuclear medicine/radiopharmaceuticals market. The report analyzes the European nuclear medicine/radiopharmaceuticals market by type, application, and country

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the European nuclear medicine/radiopharmaceuticals market

• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various European nuclear medicine/radiopharmaceuticals technologies across Europe

• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the European nuclear medicine/radiopharmaceuticals market

• Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the European nuclear medicine/radiopharmaceuticals market

”

“TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH METHODOLOGY STEPS 23
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 24
2.2.1 SECONDARY RESEARCH 24
2.2.2 PRIMARY RESEARCH 25
2.2.3 KEY INDUSTRY INSIGHTS 25
2.3 KEY DATA FROM PRIMARY SOURCES 26
2.4 KEY INSIGHTS FROM PRIMARY SOURCES 27
2.5 MARKET SIZE ESTIMATION METHODOLOGY 27
2.6 RESEARCH DESIGN 29
2.7 MARKET DATA VALIDATION AND TRIANGULATION 30
2.8 ASSUMPTIONS FOR THE STUDY 30
3 EXECUTIVE SUMMARY 31
3.1 INTRODUCTION 31
3.2 CURRENT SCENARIO 32
3.3 FUTURE OUTLOOK 32
4 PREMIUM INSIGHTS 35
4.1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 35
4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY COUNTRY AND APPLICATION 36
4.3 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY 37
4.4 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020) 38
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 40
5.2.1.1 Increasing preference for SPECT and PET scans 40
5.2.1.2 Advances in radiotracers 41
5.2.1.3 Alpha radioimmunotherapy-based targeted cancer treatment 41
5.2.1.4 Growing incidence rate of cancer and cardiac ailments 42
5.2.2 RESTRAINTS 43
5.2.2.1 Shorter half-life of radiopharmaceuticals 43
5.2.2.2 Competition from conventional diagnostic procedures 43
5.2.3 OPPORTUNITIES 43
5.2.3.1 Potential radioisotopes in the pipeline 43
5.2.3.2 Cyclotron-based production 44
5.2.4 CHALLENGE 45
5.2.4.1 Shutdown of nuclear reactors 45
5.2.5 BURNING ISSUE 45
5.2.5.1 Low healthcare spending in Europe 45
5.3 REGULATORY SCENARIO 46
5.3.1 INTRODUCTION 46
5.3.2 GERMANY 46
5.3.2.1 German Medicinal Products Act (AMG) 46
5.3.2.2 Amendments to the German Medicinal Products Act (AMG) 46
5.3.3 FRANCE 47
5.3.3.1 Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) 47
5.3.4 U.K. 47
5.3.4.1 The Medicines and Healthcare Products Regulatory Agency (MHRA) 47
5.3.5 SPAIN 47
5.3.6 ITALY 48
5.3.6.1 The Italian Pharmaceutical Agency (AIFA) 48
5.3.7 RUSSIA 48
5.3.7.1 The Federal Law 48
5.3.8 SWITZERLAND 48
5.3.8.1 Federal Department Of Home Affairs (FDHA)- The Ultimate Decision Maker 48
5.3.8.2 The Swiss Agency For Therapeutic Products (SATP) 49
6 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, PIPELINE ASSESSMENT 50
6.1 INTRODUCTION 51
6.2 DIAGNOSTIC RADIOISOTOPES 53
6.2.1 F-18 55
6.3 THERAPEUTIC RADIOISOTOPES 57
6.3.1 RA-223 59
6.3.2 LU-177 61
7 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 
BY TYPE 63
7.1 INTRODUCTION 64
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS 65
7.2.1 SPECT RADIOPHARMACEUTICALS 67
7.2.1.1 Technetium-99m 68
7.2.1.2 Thallium-201 69
7.2.1.3 Gallium-67 70
7.2.1.4 Iodine-123 71
7.2.1.5 Others 72
7.2.2 PET RADIOPHARMACEUTICALS 73
7.2.2.1 Fluorine-18 74
7.2.2.2 Rubidium-82 75
7.2.2.3 Others 76
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS 77
7.3.1 BETA EMITTERS 79
7.3.1.1 Iodine-131 80
7.3.1.2 Yttrium-90 81
7.3.1.3 Samarium-153 82
7.3.1.4 Rhenium-186 83
7.3.1.5 Lutetium-177 84
7.3.1.6 Others 84
7.3.2 ALPHA EMITTERS 85
7.3.2.1 Radium-223 86
7.3.3 BRACHYTHERAPY 86
7.3.3.1 Iodine-125 88
7.3.3.2 Iridium-192 89
7.3.3.3 Palladium-103 89
7.3.3.4 Cesium-131 90
7.3.3.5 Others 91
8 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 
BY APPLICATION 92
8.1 INTRODUCTION 93
8.2 DIAGNOSTIC APPLICATIONS 93
8.2.1 SPECT APPLICATIONS 93
8.2.1.1 Cardiology 96
8.2.1.2 Lymphoma 97
8.2.1.3 Neurology 98
8.2.1.4 Thyroid 99
8.2.1.5 Other SPECT Applications 100
8.2.2 PET APPLICATIONS 101
8.2.2.1 Oncology 104
8.2.2.2 Cardiology 104
8.2.2.3 Neurology 105
8.2.2.4 Other PET Applications 106
8.3 THERAPEUTIC APPLICATIONS 107
8.3.1 THYROID 110
8.3.2 BONE METASTASIS 111
8.3.3 LYMPHOMA 112
8.3.4 ENDOCRINE TUMORS 113
8.3.5 OTHER THERAPEUTIC APPLICATIONS 114
9 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS, PROCEDURAL VOLUME 116
9.1 INTRODUCTION 117
9.2 EUROPEAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME 118
9.2.1 SPECT RADIOPHARMACEUTICALS 118
9.2.2 PET RADIOPHARMACEUTICALS 119
9.3 EUROPEAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME 119
9.3.1 BETA EMITTERS 120
9.3.2 ALPHA EMITTERS 120
9.3.3 BRACHYTHERAPY 121
10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 
BY COUNTRY/REGION 122
10.1 INTRODUCTION 123
10.2 GERMANY 126
10.3 FRANCE 131
10.4 ITALY 136
10.5 U.K. 141
10.6 SPAIN 146
10.7 RUSSIA 151
10.8 REST OF EUROPE (ROE) 156
11 COMPETITIVE LANDSCAPE 162
11.1 OVERVIEW 162
11.2 COMPETITIVE SITUATION AND TRENDS 162
11.2.1 INTRODUCTION 162
11.2.2 AGREEMENTS & CONTRACTS 163
11.2.3 ACQUISITIONS 164
11.2.4 MARKET DEVELOPMENTS 164
11.2.5 EXPANSIONS 165
11.2.6 OTHER STRATEGIES 165
12 COMPANY PROFILES 166
(Overview, Financials, Products & Services, Strategy, and Developments)*
12.1 CARDINAL HEALTH, INC. 166
12.2 MALLINCKRODT PLC 168
12.3 GE HEALTHCARE 170
12.4 LANTHEUS MEDICAL IMAGING, INC. 172
12.5 BAYER HEALTHCARE 174
12.6 BRACCO IMAGING S.P.A 176
12.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS 178
12.8 NORDION, INC. 180
12.9 ADVANCED ACCELERATOR APPLICATIONS S.A. 182
12.10 IBA MOLECULAR IMAGING 184
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.
13 APPENDIX 186
13.1 DISCUSSION GUIDE 186
13.2 AVAILABLE CUSTOMIZATIONS 194
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 194
13.4 RELATED REPORTS 195
“
“LIST OF TABLES

TABLE 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 42
TABLE 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 43
TABLE 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 44
TABLE 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 45
TABLE 5 LOW HEALTHCARE SPENDING IN EUROPE IS A MAJOR BURNING ISSUE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 46
TABLE 6 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS 54
TABLE 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS 58
TABLE 8 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013-2020 (USD MILLION) 65
TABLE 9 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,  BY COUNTRY, 2013-2020 (USD MILLION) 66
TABLE 10 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,  BY TYPE, 2013-2020 (USD MILLION) 66
TABLE 11 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,  
BY COUNTRY, 2013-2020 (USD MILLION) 68
TABLE 12 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,  
BY ISOTOPE TYPE, 2013-2020 (USD MILLION) 68
TABLE 13 EUROPE: TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 69
TABLE 14 EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 70
TABLE 15 EUROPE: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 71
TABLE 16 EUROPE: IODINE-123 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 72
TABLE 17 EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY,  
2013-2020 (USD MILLION) 73
TABLE 18 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,  
BY COUNTRY, 2013-2020 (USD MILLION) 74
TABLE 19 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,  
BY ISOTOPE TYPE, 2013-2020 (USD MILLION) 74
TABLE 20 EUROPE: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 75
TABLE 21 EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 76
TABLE 22 EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 
2013-2020 (USD MILLION) 77
TABLE 23 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 78
TABLE 24 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 78
TABLE 25 EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 80
TABLE 26 EUROPE: BETA EMITTERS MARKET SIZE, BY ISOTOPE TYPE, 
2013-2020 (USD MILLION) 80
TABLE 27 EUROPE: IODINE-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 81
TABLE 28 EUROPE: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 82
TABLE 29 EUROPE: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 83
TABLE 30 EUROPE: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 83
TABLE 31 EUROPE: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 84
TABLE 32 EUROPE: OTHER BETA EMITTER ISOTOPES MARKET SIZE, BY COUNTRY,  
2013-2020 (USD MILLION) 85
TABLE 33 EUROPE: ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 
2013-2020 (USD MILLION) 86
TABLE 34 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY,  
2013-2020 (USD MILLION) 87
TABLE 35 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY ISOTOPE TYPE,  
2013-2020 (USD MILLION) 88
TABLE 36 EUROPE: IODINE-125 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 88
TABLE 37 EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 89
TABLE 38 EUROPE: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 90
TABLE 39 EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 90
TABLE 40 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY,  
2013-2020 (USD MILLION) 91
TABLE 41 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 94
TABLE 42 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION) 95
TABLE 43 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 97
TABLE 44 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 98
TABLE 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 99
TABLE 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 100
TABLE 47 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 100
TABLE 48 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 102
TABLE 49 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION) 103
TABLE 50 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 104
TABLE 51 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 105
TABLE 52 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 106
TABLE 53 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 107
TABLE 54 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 108
TABLE 55 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION) 109
TABLE 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 111
TABLE 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 112
TABLE 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 113
TABLE 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 114
TABLE 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 115
TABLE 61 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND) 117
TABLE 62 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY COUNTRY, 2013–2020 (THOUSAND) 117
TABLE 63 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND) 118
TABLE 64 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND) 118
TABLE 65 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND) 119
TABLE 66 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND) 119
TABLE 67 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BETA EMITTERS, 
BY TYPE,  2013–2020 (THOUSAND) 120
TABLE 68 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR ALPHA EMITTERS, 
BY TYPE,  2013–2020 (THOUSAND) 120
TABLE 69 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BRACHYTHERAPY, 
BY TYPE,  2013–2020 (THOUSAND) 121
TABLE 70 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, 
BY COUNTRY, 2013–2020 (USD MILLION) 124
TABLE 71 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, 
BY TYPE, 2013–2020 (USD MILLION) 126
TABLE 72 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 127
TABLE 73 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY TYPE, 2013–2020 (USD MILLION) 127
TABLE 74 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  BY TYPE, 2013–2020 (USD MILLION) 128
TABLE 75 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 128
TABLE 76 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 129
TABLE 77 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 129
TABLE 78 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 130
TABLE 79 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  BY APPLICATION, 2013–2020 (USD MILLION) 130
TABLE 80 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION) 131
TABLE 81 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013–2020 (USD MILLION) 132
TABLE 82 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 132
TABLE 83 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY TYPE, 2013–2020 (USD MILLION) 132
TABLE 84 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  BY TYPE, 2013–2020 (USD MILLION) 133
TABLE 85 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 133
TABLE 86 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 134
TABLE 87 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 134
TABLE 88 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 135
TABLE 89 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  BY APPLICATION, 2013–2020 (USD MILLION) 135
TABLE 90 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION) 136
TABLE 91 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013–2020 (USD MILLION) 136
TABLE 92 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 137
TABLE 93 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY TYPE, 2013–2020 (USD MILLION) 137
TABLE 94 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, 
BY TYPE, 2013–2020 (USD MILLION) 138
TABLE 95 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 138
TABLE 96 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 139
TABLE 97 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 139
TABLE 98 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 140
TABLE 99 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  
BY APPLICATION, 2013–2020 (USD MILLION) 140
TABLE 100 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY APPLICATION, 2013–2020 (USD MILLION) 141
TABLE 101 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013–2020 (USD MILLION) 142
TABLE 102 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 142
TABLE 103 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, 
BY TYPE, 2013–2020 (USD MILLION) 142
TABLE 104 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, 
BY TYPE, 2013–2020 (USD MILLION) 143
TABLE 105 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 143
TABLE 106 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 144
TABLE 107 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 144
TABLE 108 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 145
TABLE 109 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  
BY APPLICATION, 2013–2020 (USD MILLION) 145
TABLE 110 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY APPLICATION, 2013–2020 (USD MILLION) 146
TABLE 111 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013–2020 (USD MILLION) 147
TABLE 112 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 147
TABLE 113 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY TYPE, 2013–2020 (USD MILLION) 147
TABLE 114 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, 
BY TYPE, 2013–2020 (USD MILLION) 148
TABLE 115 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 148
TABLE 116 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 149
TABLE 117 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 149
TABLE 118 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 150
TABLE 119 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  
BY APPLICATION, 2013–2020 (USD MILLION) 150
TABLE 120 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY APPLICATION, 2013–2020 (USD MILLION) 151
TABLE 121 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013–2020 (USD MILLION) 152
TABLE 122 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 152
TABLE 123 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY TYPE, 2013–2020 (USD MILLION) 152
TABLE 124 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION) 153
TABLE 125 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 153
TABLE 126 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 154
TABLE 127 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 154
TABLE 128 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 155
TABLE 129 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  BY APPLICATION, 2013–2020 (USD MILLION) 155
TABLE 130 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION) 156
TABLE 131 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE,  2013–2020 (USD MILLION) 157
TABLE 132 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE,  BY TYPE, 2013–2020 (USD MILLION) 157
TABLE 133 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, 
BY TYPE, 2013–2020 (USD MILLION) 158
TABLE 134 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, 
BY TYPE, 2013–2020 (USD MILLION) 158
TABLE 135 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 159
TABLE 136 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION) 159
TABLE 137 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION) 160
TABLE 138 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT,  BY APPLICATION, 2013–2020 (USD MILLION) 160
TABLE 139 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET,  
BY APPLICATION, 2013–2020 (USD MILLION) 161
TABLE 140 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE,  BY APPLICATION, 2013–2020 (USD MILLION) 161
TABLE 141 AGREEMENTS & CONTRACTS, 2012-2015 163
TABLE 142 ACQUISITIONS, 2012-2015 164
TABLE 143 MARKET DEVELOPMENTS, 2012-2015 164
TABLE 144 EXPANSIONS, 2012-2015 165
TABLE 145 OTHER STRATEGIES, 2012-2015 165
“
“LIST OF FIGURES

FIGURE 1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION 21
FIGURE 2 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS 23
FIGURE 3 KEY DATA FROM SECONDARY SOURCES 24
FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 26
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 28
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 28
FIGURE 7 RESEARCH DESIGN 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 30
FIGURE 9 THERAPEUTIC MARKET TO WITNESS HIGH GROWTH RATE FROM 2015 TO 2020 31
FIGURE 10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SHARE, BY TYPE, 2015 VS. 2020 32
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 2015 33
FIGURE 12 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS MARKET SIZE, 2015 VS. 2020 34
FIGURE 13 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH 35
FIGURE 14 GERMANY DOMINATES THE EUROPEAN SPECT NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015 36
FIGURE 15 REST OF EUROPE TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 37
FIGURE 16 DIAGNOSTIC SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD 38
FIGURE 17 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 40
FIGURE 18 CLINICAL TRIALS STUDIES OF RADIOISOTOPES, BY COUNTRY 51
FIGURE 19 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE 52
FIGURE 20 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES,  BY COMPANY & INSTITUTE 52
FIGURE 21 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE 53
FIGURE 22 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE 53
FIGURE 23 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION 54
FIGURE 24 CLINICAL TRIALS FOR F-18, BY COUNTRY 55
FIGURE 25 CLINICAL TRIALS FOR F-18, BY PHASE 55
FIGURE 26 CLINICAL TRIALS FOR F-18, BY INDICATION 56
FIGURE 27 CLINICAL TRIALS FOR F-18, BY COMPANY/INSTITUTE 56
FIGURE 28 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE 57
FIGURE 29 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION 58
FIGURE 30 CLINICAL TRIALS FOR RA-223, BY COUNTRY 59
FIGURE 31 CLINICAL TRIALS FOR RA-223, BY PHASE 59
FIGURE 32 CLINICAL TRIALS FOR RA-223, BY INDICATION 60
FIGURE 33 CLINICAL TRIALS FOR RA-223, BY COMPANY/INSTITUTE 60
FIGURE 34 CLINICAL TRIALS FOR LU-177, BY COUNTRY 61
FIGURE 35 CLINICAL TRIALS FOR LU-177, BY PHASE 61
FIGURE 36 CLINICAL TRIALS FOR LU-177, BY INDICATION 61
FIGURE 37 CLINICAL TRIALS FOR LU-177, BY COMPANY/INSTITUTE 62
FIGURE 38 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE 64
FIGURE 39 THERAPEUTIC SEGMENT TO GROW AT A HIGHER CAGR OF 10.2% 65
FIGURE 40 PET SEGMENT TO GROW AT THE HIGHER CAGR OF 13.1% DURING THE FORECAST PERIOD 67
FIGURE 41 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.7% DURING THE FORECAST PERIOD 79
FIGURE 42 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE 94
FIGURE 43 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 13.2% DURING THE FORECAST PERIOD 95
FIGURE 44 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.1% DURING THE FORECAST PERIOD 96
FIGURE 45 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PET APPLICATIONS, BY TYPE 101
FIGURE 46 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 20.1% DURING THE FORECAST PERIOD 102
FIGURE 47 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.4% DURING THE FORECAST PERIOD 103
FIGURE 48 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE 108
FIGURE 49 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 16.5% DURING THE FORECAST PERIOD 109
FIGURE 50 THE ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 13.0% DURING THE FORECAST PERIOD 110
FIGURE 51 GERMANY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC IN 2015 124
FIGURE 52 THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET TO GROW AT A CAGR OF 8.2% DURING THE FORECAST PERIOD 125
FIGURE 53 BATTLE FOR MARKET SHARE: AGREEMENTS & CONTRACTS WAS THE KEY STRATEGY ADOPTED BY PLAYERS BETWEEN 2012 & 2015 162
FIGURE 54 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT 166
FIGURE 55 MALLINCKRODT PLC: COMPANY SNAPSHOT 168
FIGURE 56 GE HEALTHCARE: COMPANY SNAPSHOT 170
FIGURE 57 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT 172
FIGURE 58 BAYER HEALTHCARE: COMPANY SNAPSHOT 174
FIGURE 59 NORDION, INC.: COMPANY SNAPSHOT 180
FIGURE 60 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT 182
“